Literature DB >> 32146032

Resolving Resistance to Osimertinib Therapy With Afatinib in an NSCLC Patient With EGFR L718Q Mutation.

Xue Yang1, Chuan Huang2, Rongrong Chen3, Jun Zhao4.   

Abstract

Entities:  

Keywords:  Concomitant mutation; EGFR L858R; KRAS; Loss of T790M

Mesh：

Substances：

Year:  2020        PMID： 32146032     DOI： 10.1016/j.cllc.2019.12.002

Source DB:  PubMed          Journal:  Clin Lung Cancer        ISSN： 1525-7304            Impact factor:   4.785


× No keyword cloud information.
  7 in total

Review 1.  The next tier of EGFR resistance mutations in lung cancer.

Authors:  Hannah L Tumbrink; Alena Heimsoeth; Martin L Sos
Journal:  Oncogene       Date:  2020-10-15       Impact factor: 9.867

2.  Case Report: Dacomitinib May Not Benefit Patients Who Develop Rare Compound Mutations After Later-Line Osimertinib Treatment.

Authors:  Hong-Shuai Li; Guang-Jian Yang; Yan Wang
Journal:  Front Oncol       Date:  2021-04-15       Impact factor: 6.244

Review 3.  Mechanisms and management of 3rd‑generation EGFR‑TKI resistance in advanced non‑small cell lung cancer (Review).

Authors:  Jingyi He; Zhengrong Huang; Linzhi Han; Yan Gong; Conghua Xie
Journal:  Int J Oncol       Date:  2021-09-24       Impact factor: 5.650

4.  Case Report: Dacomitinib Overcomes Osimertinib Resistance in NSCLC Patient Harboring L718Q Mutation: A Case Report.

Authors:  Qian Shen; Jingjing Qu; Zhen Chen; Jianying Zhou
Journal:  Front Oncol       Date:  2021-12-02       Impact factor: 6.244

Review 5.  Acquired Mechanisms of Resistance to Osimertinib-The Next Challenge.

Authors:  Alejandro Ríos-Hoyo; Laura Moliner; Edurne Arriola
Journal:  Cancers (Basel)       Date:  2022-04-12       Impact factor: 6.575

6.  Case Report: Durable Response to the Combination of Brigatinib and Cetuximab Plus Icotinib in a NSCLC Patient Harboring EGFR L858R-T790M-cis-G796S and L718Q Resistance Mutations Following Progression With Osimertinib.

Authors:  Yubo Wang; Rui Han; Mengxiao Zhu; Tingting He; Yong He
Journal:  Front Oncol       Date:  2022-04-21       Impact factor: 5.738

Review 7.  "Sandwich" Strategy to Intensify EGFR Blockade by Concurrent Tyrosine Kinase Inhibitor and Monoclonal Antibody Treatment in Highly Selected Patients.

Authors:  Guoqing Zhang; Beibei Yan; Yanan Guo; Hang Yang; Jindong Li
Journal:  Front Oncol       Date:  2022-07-08       Impact factor: 5.738
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.